Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)
Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects With Painful Lumbar Radiculopathy
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Leiden, Holland
- Center for Human Drug Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria: Part I and Part II
- Healthy Volunteers
Key Inclusion Criteria: Part III multiple ascending dose (MAD)
- Subjects must have a diagnosis of unilateral painful lumbar radiculopathy and painful lumbar radiculopathy symptoms must be present for 3 or more months prior to the Screening Visit.
- Subjects must rate their pain at ≥40 mm on the 100 mm visual analog scale (VAS) of the short form McGill pain questionnaire (SF-MPQ) at the Screening and Baseline Visits.
Key Inclusion Criteria for All Subjects for Part I, Part II, Part III:
- All male subjects and all female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 3 months after their last dose of study treatment. -
Key Exclusion Criteria for All Subjects for Part I, Part II, Part III:
- History of or positive screening test for hepatitis C infection , hepatitis B infection, or positive for human immunodeficiency virus (HIV) antibody. Subjects who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive are allowed to participate if they are positive for HBsAb immunoglobulin G
- History of malignancy or clinically relevant (as determined by the Investigator) allergies; cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (not related to painful lumbar radiculopathy), dermatologic, rheumatic/joint, psychiatric, renal, and/or other major disease.
- Relevant history of illicit drug or alcohol abuse (as defined by the Investigator) within 1 year prior to the Screening Visit. -
- Female subjects who are pregnant or currently breastfeeding, or who have a positive pregnancy test result at the Screening or Baseline Visits.
- Previous administration of a neurotrophic factor, including BG00010.
- Participation in a study with another investigational drug or approved therapy for investigational use within the 3 months prior to the Baseline Visit, or current enrollment in any other study.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Single Ascending Dose (SAD): BG00010
Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
|
Ascending Doses intravenous (IV) of BG00010
Andre navne:
Ascending Doses subcutaneous (SC) of BG00010
Andre navne:
|
|
Eksperimentel: SAD: Placebo
Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
|
Ascending Doses intravenous (IV) of Placebo
Ascending Doses subcutaneous (SC) of placebo
|
|
Eksperimentel: Multiple Ascending Dose (MAD): BG00010
Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
|
Ascending Doses subcutaneous (SC) of BG00010
Andre navne:
|
|
Eksperimentel: Multiple Ascending Dose (MAD): Placebo
Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
|
Ascending Doses subcutaneous (SC) of placebo
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)
Tidsramme: Up to Day 75
|
Up to Day 75
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum observed concentration (Cmax) of BG00010
Tidsramme: Pre-dose and up to 24 hours post-dose
|
Pre-dose and up to 24 hours post-dose
|
|
|
Time to maximum serum concentration (Tmax) of BG00010
Tidsramme: Pre-dose and up to 24 hours post-dose
|
Pre-dose and up to 24 hours post-dose
|
|
|
Half life (t1/2) of BG00010
Tidsramme: Pre-dose and up to 24 hours post-dose
|
Pre-dose and up to 24 hours post-dose
|
|
|
Area under the serum concentration time curve (AUC) from zero to infinity AUC(0-∞) for BG00010
Tidsramme: Pre-dose and up to 24 hours post-dose
|
Pre-dose and up to 24 hours post-dose
|
|
|
Subcutaneous (SC) bioavailability
Tidsramme: Pre-dose and up to 24 hours post-dose
|
Pre-dose and up to 24 hours post-dose
|
|
|
Number of participants with anti-BG00010 antibodies in serum
Tidsramme: Up to Day 75
|
Up to Day 75
|
|
|
Pain as measured by an 11-point numeric rating scale (NRS)
Tidsramme: Up to Day 75
|
The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain.
The scale ranges from 0 (no pain) to 10 (worst pain imaginable).
|
Up to Day 75
|
|
Pain as measured by short form McGill pain questionnaire (SF-MPQ) visual analog scale (VAS)
Tidsramme: Up to Day 75
|
A 10 cm visual analog scale ranging from 0 (no pain) to 10 (worst possible pain).
|
Up to Day 75
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 103NS103
- 2012-005224-15 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .